Disclosure under SEBI Takeover Regulations

Docusign Envelope ID: A7B227BB-8EEA-4110-8EB5-A5027CE19762 7 April 2026 To To The Manager The Manager Department of Corporate Services Listing Department BSE Limited National Stock Exchange of India 25th Floor, P. J. Towers, Limited Dalal Street, Mumbai - 400001 Exchange Plaza, Bandra Kurla Complex Bandra (E), Mumbai – 400051 Scrip Code: 543064 Scrip Symbol: COHANCE Dear Sir/Madam, Sub: Declaration under Regulation 31(4) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011 (“SEBI Takeover Regulations”) Pursuant to Regulation 31(4) of the SEBI Takeover Regulations, we, Berhyanda Limited, promoter of Cohance Lifesciences Limited (Formerly, Suven Pharmaceuticals Limited), along with following persons acting in concert with Berhyanda Limited i.e., Jusmiral Holdings Limited (Promoter), Berhyanda Midco Limited and Jusmiral Midco Limited, hereby declare that we have not made any encumbrance on the shares of Cohance Lifesciences Limited (Formerly, Suven Pharmaceuticals Limited), directly or indirectly, other than those already disclosed during the financial year 2025-26. This is for your information and record. Thanking you, Yours faithfully, For Berhyanda Limited Christodoulos Patsalides Director Copy to: The Audit Committee of Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited)